Therapeutic vaccines for tuberculosis-A systematic review

Vaccine

Volumn 32, Issue 26, 2014, Pages 3162-3168

  Gröschel, Matthias I ^a   Prabowo, Satria A ^a   Cardona, Père Joan ^b   Stanford, John L ^c   Van der Werf, Tjip S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunotherapy; M. indicus pranii; M. smegmatis; Mycobacterium vaccae; RUTI; Systematic review; Therapeutic vaccine; Tuberculosis; V5 immunitor

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE SYNTHASE; RANTES; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL LOAD; CLINICAL EVALUATION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MYCOBACTERIUM VACCAE; NONHUMAN; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS;

IMMUNOTHERAPY; M. INDICUS PRANII; M. SMEGMATIS; MYCOBACTERIUM VACCAE; RUTI; SYSTEMATIC REVIEW; THERAPEUTIC VACCINE; TUBERCULOSIS; V5 IMMUNITOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, INACTIVATED;

EID: 84900427457     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.047     Document Type: Review

References (83)

1. Zumla A., Raviglione M., Hafner R., von Reyn C.F. Tuberculosis. N Engl J Med 2013, 368:745-755.
2. Marais B.J., Raviglione M.C., Donald P.R., Harries A.D., Kritski A.L., Graham S.M., et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 2010, 375:2179-2191.
3. Zumla A., Kim P., Maeurer M., Schito M. Zero deaths from tuberculosis: progress, reality, and hope. Lancet Infect Dis 2013, 13:285-287.
4. Schon T., Lerm M., Stendahl O. Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis. J Intern Med 2013, 273:368-382.
5. Li S., Luo X. Compendium of materia medica (Bencao gangmu) 2003, Foreign Languages Press, Changchun City, Jilin Province, China.
6. Kaufmann S.H., Winau F. From bacteriology to immunology: the dualism of specificity. Nat Immunol 2005, 6:1063-1066.
7. Vilaplana C., Cardona P.J. Tuberculin immunotherapy: its history and lessons to be learned. Microbes Infect 2010, 12:99-105.
8. Gradmann C. Robert Koch and the white death: from tuberculosis to tuberculin. Microbes Infect 2006, 8:294-301.
9. Kaufmann S.H. Immune response to tuberculosis: experimental animal models. Tuberculosis 2003, 83:107-111.
10. Howells C.H., Swithinbank J. A trial of tuberculin with chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1957, 38:1-15.
11. Prabowo S.A., Groschel M.I., Schmidt E.D., Skrahina A., Mihaescu T., Hasturk S., et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013, 202:95-104.
12. Bourinbaiar A.S., Mezentseva M.V., Butov D.A., Nyasulu P.S., Efremenko Y.V., Jirathitikal V., et al. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti-Infect Ther 2012, 10:381-389.
13. Guo S., Zhao J. Immunotherapy for tuberculosis: what's the better choice. Front Biosci 2012, 17:2684-2690.
14. Lin L., Tan B., Pantapalangkoor P., Ho T., Baquir B., Tomaras A., et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 2012, 3(5). pii:e00312-12.
15. Vilaplana C., Montane E., Pinto S., Barriocanal A.M., Domenech G., Torres F., et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116.
16. Stanford J., Stanford C., Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci: J Virtual Lib 2004, 9:1701-1719.
17. Changhong S., Hai Z., Limei W., Jiaze A., Li X., Tingfen Z., et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis 2009, 89:54-61.
18. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271.
19. You Q., Jiang C., Kong W., Wu Y. Attempted immunotherapy for Mycobacterium tuberculosis with viral and protein vaccines based on Ag85B-ESAT6 in a mouse model. Acta Microbiol Immunol Hung 2012, 59:63-75.
20. Yu D.H., Hu X.D., Cai H. Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther 2008, 15:652-659.
21. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clin Trials 1996, 17:1-12.
22. Cardona P.J., Amat I., Gordillo S., Arcos V., Guirado E., Diaz J., et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005, 23:1393-1398.
23. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis 2006, 86:273-289.
24. Guirado E., Gil O., Caceres N., Singh M., Vilaplana C., Cardona P.J. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol: CVI 2008, 15:1229-1237.
25. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000, 30:3689-3698.
26. Gil O., Guirado E., Gordillo S., Diaz J., Tapia G., Vilaplana C., et al. Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. Microbes Infect 2006, 8:628-636.
27. Vilaplana C., Gil O., Caceres N., Pinto S., Diaz J., Cardona P.J. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 2011, 6:e20404.
28. de Val Perez B., Lopez-Soria S., Nofrarias M., Martin M., Vordermeier H.M., Villarreal-Ramos B., et al. Experimental model of tuberculosis in the domestic goat after endobronchial infection with Mycobacterium caprae. Clin Vaccine Immunol: CVI 2011, 18:1872-1881.
29. Domingo M., Gil O., Serrano E., Guirado E., Nofrarias M., Grassa M., et al. Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. Scand J Immunol 2009, 69:500-507.
30. Gil O., Diaz I., Vilaplana C., Tapia G., Diaz J., Fort M., et al. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS One 2010, 5:e10030.
31. Cardona P.J., Amat I. Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection. Arch Bronconeumol 2006, 42:25-32.
32. Gil O., Vilaplana C., Guirado E., Diaz J., Caceres N., Singh M., et al. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol: CVI 2008, 15:1742-1744.
33. Boenickse R., Juhasz E. [Description of the New Species Mycobacterium Vaccae N. Sp]. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene 1 Abt Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie Originale. Zentralbl Bakteriol Orig. 1964, 192:133-135.
34. Pozniak A., Stanford J.L., Rook G.A. Preliminary studies of immunotherapy of tuberculosis in man. Proceedings of the International Tuberculosis Congress, Singapore (1986) 1987, 39-40. Bulletin of the International Union Against Tuberculosis, 62.
35. Hachem R., Raad I., Rolston K.V., Whimbey E., Katz R., Tarrand J., et al. Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin Infect Dis: Off Publ Infect Dis Soc Am 1996, 23:173-175.
36. Stanford J.L., Paul R.C. A preliminary report on some studies of environmental mycobacteria. Ann Soc Belge Med Trop 1973, 53:389-393.
37. Stanford J.L., Rook G.A., Bahr G.M., Dowlati Y., Ganapati R., Ghazi Saidi K., et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990, 8:525-530.
38. Collins F.M. Kinetics of the delayed-type hypersensitivity response in tuberculous guinea pigs and mice tested with several mycobacterial antigen preparations. Am Rev Respir Dis 1983, 127:599-604.
39. Stanford J.L., Grange J.M. The promise of immunotherapy for tuberculosis. Respir Med 1994, 88:3-7.
40. Skinner M.A., Yuan S., Prestidge R., Chuk D., Watson J.D., Tan P.L. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997, 65:4525-4530.
41. Zhang L., Ma W., Da J. Mycobacterium vaccae influences the kinetics of Th1/Th2 cells and expression of iNOS in a marine model of experimental tuberculosis. Zhonghua jie he he hu xi za zhi=Zhonghua jiehe he huxi zazhi=Chin J Tuberc Respir Dis 2000, 23:43-46.
42. Pozniak A., Stanford J.L., Grange J.M. Mycobacterium vaccae immunotherapy. Lancet 1991, 338:1533-1534.
43. Stanford J.L., Bahr G.M., Rook G.A., Shaaban M.A., Chugh T.D., Gabriel M., et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990, 71:87-93.
44. Bahr G.M., Shaaban M.A., Gabriel M., al-Shimali B., Siddiqui Z., Chugh T.D., et al. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 1990, 71:259-266.
45. Corlan E., Marica C., Macavei C., Stanford J.L., Stanford C.A. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respir Med 1997, 91:13-19.
46. Corlan E., Marica C., Macavei C., Stanford J.L., Stanford C.A. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 1997, 91:21-29.
47. Luo Y., Lu S., Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua jie he he hu xi za zhi=Zhonghua jiehe he huxi zazhi=Chin J Tuberc Respir Dis 2000, 23:85-88.
48. Stanford J.L., Stanford C.A., Grange J.M., Lan N.N., Etemadi A. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis. Respir Med 2001, 95:444-447.
49. Johnson J.L., Kamya R.M., Okwera A., Loughlin A.M., Nyole S., Hom D.L., et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J Infect Dis 2000, 181:1304-1312.
50. Stanford J.L., Grange J.M. New concepts for the control of tuberculosis in the twenty first century. J R Coll Physician London 1993, 27:218-223.
51. van der Werf T.S. Tuberculosis in Africa-any news. Trop Geogr Med 1994, 46:271-274.
52. Kon O.M., Goyal M., Filley E., Gleissberg G., Cunningham D., Rook G.A., et al. Mycobacterium vaccae: a study of safety and outcome measures. Respir Med 1998, 92:597-598.
53. Shield M.J., Stanford J.L., Garbajosa G., Draper P., Rees R.J. The epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from armadillo-derived Mycobacterium leprae Part 1: Leprosy patients. Int J Lepr Other Mycobact Dis: Off Organ Int Lep Assoc 1982, 50:436-445.
54. Nye P.M., Price J.E., Revankar C.R., Rook G.A., Stanford J.L. The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Lep Rev 1983, 54:9-18.
55. Stanford J.L. Improving on BCG. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 1991, 99:103-113.
56. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog 2012, 8:e1002607.
57. Weltman A.C., Rose D.N. The safety of Bacille Calmette-Guerin vaccination in HIV infection and AIDS. AIDS 1993, 7:149-157.
58. Mwinga A., Nunn A., Ngwira B., Chintu C., Warndorff D., Fine P., et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002, 360:1050-1055.
59. Marsh B.J. Fordham von Reyn C, Arbeit RD, Morin P. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci 1997, 313:377-383.
60. Anonymous. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group, Lancet 1999; 354 (9173) 116-119.
61. Mayo R.E., Stanford J.L. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans R Soc Trop Med Hyg 2000, 94:563-568.
62. de Bruyn G., Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003, (1):CD001166.
63. Stanford J.L. Immunotherapy with Mycobacterium vaccae in the treatment of mycobacterial disease. J Infect 1999, 39:179-182.
64. Dlugovitzky D., Fiorenza G., Farroni M., Bogue C., Stanford C., Stanford J. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Resp Med 2006, 100:1079-1087.
65. Dlugovitzky D., Notario R., Martinel-Lamas D., Fiorenza G., Farroni M., Bogue C., et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2010, 2:159-169.
66. Dlugovitzky D., Stanford C., Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy 2011, 3:557-568.
67. Fan M.Y., Chen X.R., Wang K., Mao H., Feng Y.L., Tang X.Y. Adjuvant effect of Mycobacterium vaccae on treatment of recurrent treated pulmonary tuberculosis: a meta-analysis. Chin J Evidence Based Med 2007, 7:449-455.
68. Hernandez-Pando R., Aguilar D., Orozco H., Cortez Y., Brunet L.R., Rook G.A. Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in BALB/c mice with pulmonary tuberculosis. Clin Vaccine Immunol: CVI 2008, 15:1730-1736.
69. Rodriguez-Guell E., Agusti G., Corominas M., Cardona P.J., Luquin M., Julian E. Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton. Clin Vaccine Immunol: CVI 2008, 15:893-896.
70. Rodriguez-Guell E., Agusti G., Corominas M., Luquin M., Julian E. Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis. Clin Vaccine Immunol: CVI 2008, 15:1485-1488.
71. Stanford J., Stanford C., Dlugovitzky D., Fiorenza G., Martinel-Lamas D., Selenscig D., et al. Potential for immunotherapy with heat-killed Mycobacterium vaccae in respiratory medicine. Immunotherapy 2009, 1:933-947.
72. Xu L.J., Wang Y.Y., Zheng X.D., Gui X.D., Tao L.F., Wei H.M. Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice. Cell Mol Immunol 2009, 6:67-72.
73. Yang X.Y., Chen Q.F., Li Y.P., Wu S.M. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011, 6:e23826.
74. Efremenko Y.V., Butov D.A., Prihoda N.D., Zaitzeva S.I., Yurchenko L.V., Sokolenko N.I., et al. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccines Immunother 2013, 9(9):1852-1856.
75. Butov D.A., Efremenko Y.V., Prihoda N.D., Zaitzeva S.I., Yurchenko L.V., Sokolenko N.I., et al. (Forthcoming) Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy 2013, 5:1-8.
76. Johnson J.L., Nunn A.J., Fourie P.B., Ormerod L.P., Mugerwa R.D., Mwinga A., et al. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Int J Tuberc Lung Dis: Off J Int Union Against Tuberc Lung Dis 2004, 8:1348-1354.
77. Baghaei P., Tabarsi P., Chitsaz E., Saleh M., Marjani M., Shemirani S., et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010, 17:17-22.
78. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
79. Singla R., Sharma S.K., Mohan A., Makharia G., Sreenivas V., Jha B., et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010, 132:81-86.
80. Warmelink I., ten Hacken N.H., van der Werf T.S., van Altena R. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2011, 105:400-408.
81. Shang P., Xia Y., Liu F., Wang X., Yuan Y., Hu D., et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011, 6:e21836.
82. Grange J.M., Bottasso O., Stanford C.A., Stanford J.L. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26:4984-4990.
83. Stanford J.L., Stanford C.A., O'Brien M.E., Grange J.M. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008, 44:224-227.